Splicing-Mediated Antigen Escape from Immunotherapy for B-cell Malignancies

Blood Cancer Discov. 2022 Mar 1;3(2):87-89. doi: 10.1158/2643-3230.BCD-21-0200.

Abstract

In this issue of Blood Cancer Discovery, Zheng and colleagues identify that alternative RNA splicing of CD22 within B-cell acute lymphoblastic leukemia can result in antigen escape from CD22-targeted immunotherapies. Drug-resistant isoforms of CD22 exist within leukemic cells pretreatment and can influence response to the CD22-directed antibody-drug conjugate inotuzumab ozogamicin, the immunotoxin moxetumomab pasudotox, as well as anti-CD22 chimeric antigen receptor T cells. See related article by Zheng et al., p. 103 (7).

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Antigenic Drift and Shift
  • Humans
  • Immunotherapy
  • Immunotoxins* / therapeutic use
  • Inotuzumab Ozogamicin
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Sialic Acid Binding Ig-like Lectin 2 / therapeutic use

Substances

  • CD22 protein, human
  • Immunotoxins
  • Sialic Acid Binding Ig-like Lectin 2
  • Inotuzumab Ozogamicin